Drug Type Monoclonal antibody |
Synonyms HMBD-001 |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous non-small cell lung cancer | Phase 2 | AU | 06 Feb 2024 | |
Squamous non-small cell lung cancer | Phase 2 | SG | 06 Feb 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | GB | 10 Nov 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | GB | 10 Nov 2021 | |
Bladder Cancer | Phase 2 | GB | 10 Nov 2021 | |
Bladder Cancer | Phase 2 | GB | 10 Nov 2021 | |
Castration-Resistant Prostatic Cancer | Phase 2 | GB | 10 Nov 2021 | |
Castration-Resistant Prostatic Cancer | Phase 2 | GB | 10 Nov 2021 | |
Endometrial Carcinoma | Phase 2 | GB | 10 Nov 2021 | |
Endometrial Carcinoma | Phase 2 | GB | 10 Nov 2021 |